UCB SA (OTCMKTS:UCBJF – Get Free Report) shares saw unusually-high trading volume on Tuesday . Piper Sandler restated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a research note on Monday. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.